Coronavirus stock hype proves infectious
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Surprise! There’s a tumour in which Keytruda doesn’t work
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Esmo 2019 makes for a disappointing read-across to biotech
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Esmo 2019 – mesothelioma trials contend with super-fast disease progression
A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of co-called hyperprogressors could have scuppered other trials.
Zepsyre has a path to market at last
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Keytruda looks to secure a June double play
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
World Lung preview – small-cell showdown
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
